Abstract
Microbial activities of gut commensals have been linked to several host diseases. In recent work, Roberts etal. (2018) develop therapeutics targeting microbial production of the metabolite trimethylamine (TMA), which has been linked to cardiovascular disease. This microbiota-based approach holds promise for efficacious therapies that may also reduce host side effects.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have